Annual Masterclass 2019
MPE AGM 2019 outtakes
MPE AGM 2019. Our speakers summarised the key points of their talks or at least they tried...
Myeloma Treatment Updates
Summary of the talk given by Prof. Heinz Ludwig, Wilhelminen Cancer Research Institute, Austria, about myeloma treatment updates during the MPE Annual General Meeting (AGM) held in Munich, Germany in March 2019.
Surrogate end-points in myeloma and AL amyloidosis
Summary of the talk given by Dr Moshe Gatt, Hadassah Hebrew University Medical Center, Jerusalem (Israel), on surrogate end-points and biomarkers in myeloma and AL amyloidosis during the MPE Annual General Meeting 2019 held in Munich, Germany.
Measuring and utilising quality of life
Summary of the talk given by Dr Jayne Galinsky, Health Services Research Manager at Myeloma UK, on Measuring and utilising quality of life during the MPE Annual General Meeting (AGM) held in Munich, Germany in March 2019.
AL Amyloidosis
Summary of the Plenary session on AL Amyloidosis given by Dr Moshe Gatt, Hadassah Hebrew University Medical Center, Jerusalem (Israel) and Daniel Drimer, president of Amyloidosis Israel during the MPE Annual General Meeting 2019, in Munich, Germany.
The role of CAR-T
Summary of the talk given by Dr. Michael Hudecek, University of Wuerzburg, Germany, about the role of CAR-T cells in myeloma and AL amyloidosis at the MPE Annual General Meeting 2019 held in Munich, Germany.
Annual Masterclass 2018
MPE Capacity Building Programme
Community Advisory Boards and case studies of MPE member groups
Rehabilitation, self-care and quality of life
Journey to a professional and empowered advocate
Clinical trials design and study endpoints
Myeloma related diseases
Drug access and affordability
Coping with a chronic disease
Update on diagnosis and treatment of AL amyloidosis
Annual Masterclass 2017
MPE dialogues - “Where are we now in myeloma and how does the future look like?”
Welcome, introductions and driving throught the conference
The European Atlas of Access to Myeloma Treatment
Update on current diagnosis and treatment of myeloma and related diseases
Clinical trials and drugs under development in myeloma and AL Amyloidosis
Treatment of myeloma in the light of access barriers
Patient advocate development strategies: how can an umbrella organisation help you
Annual Masterclass 2016
Treating myeloma. An update on the current myeloma treatment guidelines
Myeloma and Amyloidosis 101
What is multiple myeloma associated amyloidosis?
Advocacy session 1 – Patient involvement in clinical research
Welcome and introductions
The MPE Atlas: myeloma UK case study
Evidence based advocacy: implementing the MPE Atlas
Atlas Coaching Programme
Myeloma beyond C.R.A.B. An update on the current mueloma diagnosis guidelines